February 22, 2021August 24, 2022
Enhertu Approved in UK for Inoperable, Advanced Breast Cancer
News
Enhertu (trastuzumab deruxtecan) has been granted conditional approval in the U.K. for the treatment of adults with inoperable or metastatic ... Read more
February 18, 2021February 18, 2021
Phase 2 Trial Will Test IRX-2 Combined With Keytruda, Chemotherapy for TNBC
News
An open-label Phase 2 clinical trial will test the safety and efficacy of IRX-2, an experimental immunology-based cancer therapy, in ... Read more
February 15, 2021February 15, 2021
Tukysa Combo Approved in EU for Advanced HER2-Positive Breast Cancer
News
Seagen’s Tukysa (tucatinib) has been approved by the European Commission (EC) as part of a triple-combination therapy for people with previously ... Read more
February 11, 2021February 11, 2021
Trial Testing AL101 in TNBC Doses First Patient
News
The first participant has been dosed in the Phase 2 clinical trial TENACITY, which is evaluating Ayala Pharmaceuticals‘ investigational therapy ... Read more
February 8, 2021February 8, 2021
‘Overwhelmingly Positive’ Data Halts Endoxifen Phase 2 Trial for Invasive Cancer
News
After promising results from patients enrolled to date, Atossa Therapeutics halted an Australian Phase 2 clinical trial evaluating its investigative ... Read more
February 4, 2021February 4, 2021
Theralink Begins Testing New Biomarker Assay for Breast Cancer Tumors
News
Theralink Technologies announced that it has begun testing its new profiling biomarker assay — a test that could potentially provide ... Read more
February 1, 2021February 1, 2021
US Study Enrolling Women to Help Determine Best Screening Practices
News
A national study is seeking women in the U.S. to help determine the safest and best way to screen for ... Read more
January 28, 2021January 28, 2021
Nonprofit Highlights Importance of Global Teamwork for World Cancer Day
News
In honor of World Cancer Day on Feb. 4, the Breast International Group (BIG) emphasized the importance of wide-scale cooperation ... Read more
January 25, 2021January 25, 2021
Enhertu Approved in EU for Inoperable, Advanced Breast Cancer
News
The European Commission has conditionally approved Enhertu (trastuzumab deruxtecan) for adults in the EU with inoperable or metastatic HER2-positive breast cancer ... Read more
January 21, 2021January 21, 2021
Imagio Imaging System for Breast Cancer Diagnosis Approved by FDA
News
Imagio, Seno Medical Instruments’ non-invasive and radiation-free breast imaging technology, has been approved for commercialization by the Center for Devices and ... Read more
January 18, 2021January 18, 2021
Mindfulness Can Alter Brain’s Perception of Pain in Cancer Survivors
News
Mindfulness can significantly improve brain health and pain perception in breast cancer survivors, according to a small Canadian study. The ... Read more
January 14, 2021January 14, 2021
Genetic Test for Advanced Breast Cancer Launched in EU
News
Roche has launched a diagnostic genetic test to detect mutations in the PIK3CA gene in patients with advanced or metastatic ... Read more

May 31, 2019May 31, 2019

Prestige’s HD201, a Biosimilar to Herceptin, Accepted for Review in Europe for HER2-positive BC

News

The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) submitted by Prestige BioPharma for HD201, its lead biosimilar to Genentech‘s Herceptin (trastuzumab). Like Herceptin, HD201 ... Read more

May 29, 2019May 29, 2019

FDA Approves Piqray-Faslodex Combo for Some Patients with Advanced Breast Cancer

News

Breast cancer patients in the U.S. who are receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-), and have mutated PIK3CA can now be treated with Novartis‘ Piqray (alpelisib) ... Read more

May 28, 2019May 24, 2019

The Blonde in the Waiting Room

A Lump in the Road - A Column by Nancy Brier, Columns

A young woman weeped. Pretty blond hair swung in front of her face, but it didn’t hide her angst. From where I sat, I could feel the panic running though ... Read more

May 24, 2019

Keytruda Fails to Improve Overall Survival of Patients with Triple-Negative Breast Cancer, Phase 3 Trial Shows

News

Keytruda (pembrolizumab), Merck‘s anti-PD-1 checkpoint blockade immunotherapy, failed to prolong the overall survival of patients with metastatic triple-negative breast cancer (TNBC) beyond that provided by chemotherapy agents, a Phase 3 ... Read more

May 22, 2019

Treatment Intensity Should Be Personalized in Women with HER2-positive Breast Cancer, Study Says

News

Personalized treatment intensity is crucial to the success of less toxic and demanding therapies for women with HER2-positive breast cancer, according to a spokesperson from the European Society for Medical ... Read more

May 20, 2019

Young Women More Likely to Face Aggressive BC Types, But Proper Treatment Improves Outcomes

News

Young women are more likely than older ones to be diagnosed with more aggressive forms of breast cancer, but their outcomes can be good if they follow recommended treatments. That ... Read more

May 15, 2019

Experimental Antibody Therapy Leads to Significant Responses in HER2-positive Breast Cancer, Phase 2 Trial Shows

News

Trastuzumab deruxtecan (DS-8201), an investigational antibody-drug conjugate developed by AstraZeneca with Daiicho Sankyo, led to clinically meaningful responses in patients with advanced HER2-positive breast cancer, a Phase 2 clinical trial ... Read more

May 14, 2019May 9, 2019

Here I Am

A Lump in the Road - A Column by Nancy Brier, Columns

I remember when my daughter performed at a talent show at her school. I’d just had my fourth round of chemotherapy, and my condition was critical. For me, every chemo ... Read more

May 13, 2019

Radiation Therapy Reduces Chances of Breast Cancer Returning in Women with Early, Hormone-Positive Disease, Trial Shows

News

Women with early, low-risk hormone receptor-positive breast cancer are significantly less likely to see their disease return if given radiation therapy and hormone therapy following surgery, according to a trial ... Read more

May 10, 2019

Kadcyla Approved in US for Some HER2-positive Early Breast Cancer Patients

News

The U.S. Food and Drug Administration (FDA) has extended the use of Genentech‘s Kadcyla (ado-trastuzumab emtansine) as an adjuvant (post-surgery) treatment for some patients with HER2-positive, early-stage breast cancer, the company announced. ... Read more

May 6, 2019

SHARE Introduces My MBC & Me App for Metastatic Breast Cancer Patients

News

Since her diagnosis of metastatic breast cancer two years ago, Karen Peterson has been amid a whirlwind of medical appointments and healthcare professionals. It’s often overwhelming. “Managing it all is ... Read more

May 3, 2019

New Imaging Tool Captures Process That Turns Tumor Cells Malignant in Breast Cancer

News

A new imaging technique that visualizes individual cells with high resolution may improve the understanding of key events in breast cancer development, including how and when cells turn invasive and spread ... Read more

Enhertu Approved in UK for Inoperable, Advanced Breast Cancer

Phase 2 Trial Will Test IRX-2 Combined With Keytruda, Chemotherapy for TNBC

Tukysa Combo Approved in EU for Advanced HER2-Positive Breast Cancer

Trial Testing AL101 in TNBC Doses First Patient

‘Overwhelmingly Positive’ Data Halts Endoxifen Phase 2 Trial for Invasive Cancer

Theralink Begins Testing New Biomarker Assay for Breast Cancer Tumors

US Study Enrolling Women to Help Determine Best Screening Practices

Nonprofit Highlights Importance of Global Teamwork for World Cancer Day

Enhertu Approved in EU for Inoperable, Advanced Breast Cancer

Imagio Imaging System for Breast Cancer Diagnosis Approved by FDA

Mindfulness Can Alter Brain’s Perception of Pain in Cancer Survivors

Genetic Test for Advanced Breast Cancer Launched in EU